Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Clinical Utility of Home-to-Home Tele-neuropsychology (TeleNP) in the Assessment of Post-Operative Deep Brain Stimulation (DBS) Outcomes in Parkinson’s disease (PD) Patients
Movement Disorders
P10 - Poster Session 10 (8:00 AM-9:00 AM)
5-012

Neurologists work closely with neuropsychologists who evaluate postoperative cognitive, behavioral, and mood outcomes in PD patients. For PD patients with barriers to accessing care, home-to-home TeleNP post-DBS management provides a much-needed resource to increase care access.

The coronavirus pandemic facilitated widespread implementation of tele-neuropsychological assessment of DBS candidates due to physical distancing and safety requirements. Our prior work has demonstrated preoperative home-to-home TeleNP feasibility and patient satisfaction in determining candidacy for DBS in PD patients. To our knowledge the implementation and feasibility of TeleNP in assessing postoperative outcomes have not been assessed. 
PD patients [n=28, Mage=62.6(8.8), 75% male, Medu=16.1(3.0), 46.4% Hispanic, 64.3% pretested in English/35.7% in Spanish, 92.9% STN), underwent pre- and post-cognitive (global cognition, language, memory, attention, processing speed, visuospatial ability) and emotional assessments via home-to-home TeleNP between May 2020 and March 2022. PD patients underwent either in-person (n=23) or TeleNP (n=5) evaluation pre-DBS and in-person (n=1) or home-to-home TeleNP (n=27) assessments post-surgery. Paired t-tests were conducted to assess differences between pre and post assessments.
To date, 28 candidates completed both pre- and post-DBS neuropsychological assessment. Significant differences in semantic fluency (Animals: t(53)=3.89, d=.53, mz-diff=0.6), short- and long-delay verbal recall (CVLT: t(43)=2.95, d=.44, mz-diff=0.4 and t(47)=3.13, d=.45, mz-diff=0.4 respectively), and processing speed (SDMT: t(23)=3.57, d=.73, mz-diff=0.8) were noted at p<.005 (Bonferroni-adjusted for family-wise error), where mz-diff  represents z-score decrease from pre- to post-test. In contrast, no significant change was noted in orientation, naming, phonemic fluency, working memory, executive functioning, verbal reasoning, depression, anxiety, or PD symptom dysfunction (PDQ-39). 
TeleNP is a feasible platform for comprehensively assessing short- and long-term outcomes in PD patients post-DBS in English and Spanish. Remote care reduces the risk of patients being lost to follow-up by offering time- and cost advantages to those who have physical or transportation limitations or are living in remote areas.
Authors/Disclosures
Hannah Margaret Bullock (University of Miami - Miller School of Medicine)
PRESENTER
Ms. Bullock has nothing to disclose.
Scott Harcourt, PhD (Blue Cat Neuropsychology & Intervention, PLLC) Dr. Harcourt has nothing to disclose.
Dayana Rodriguez, PhD (University of Miami) Dr. Rodriguez has nothing to disclose.
Annelly Buré-Reyes Annelly Buré-Reyes has nothing to disclose.
Corneliu C. Luca, MD (University of Miami) Dr. Luca has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific. Dr. Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Signant Health.
Jonathan Jagid Jonathan Jagid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic Inc. The institution of Jonathan Jagid has received research support from Boston Scientific. The institution of Jonathan Jagid has received research support from Medtronic Inc.
Bonnie E. Levin, PhD No disclosure on file
Julia See Miss See has nothing to disclose.
Ihtsham Haq, MD, FAAN (University of Miami Miller School of Medicine) The institution of Dr. Haq has received research support from NINDS. The institution of Dr. Haq has received research support from the Parkinson's Foundation. The institution of Dr. Haq has received research support from NIMH. Dr. Haq has a non-compensated relationship as a consultant with Medtronics that is relevant to AAN interests or activities. Dr. Haq has a non-compensated relationship as a consultant with Boston Scientific that is relevant to AAN interests or activities. Dr. Haq has a non-compensated relationship as a consultant with Abbott that is relevant to AAN interests or activities.
Marina Sarno, Other (University of Miami Department of Neurology) Dr. Sarno has nothing to disclose.